← Back to patent-cliff list
Decitabine/Tetrahydrouridine (EpiDestiny/Novo Nordisk)
Tier C — Watch / tradeDecitabine/Tetrahydrouridine (EpiDestiny/Novo Nordisk)
Epicdestiny
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CDA, DNMT1
Indications (approved)：血细胞减少症, Sickle cell disease, Myelodysplastic syndrome
Regional status
US
Phase II
2022-07-07
EU
Phase II
2022-07-07
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Decitabine/Tetrahydrouridine (EpiDestiny/Novo Nordisk)?
Approved indications include: 血细胞减少症, Sickle cell disease, Myelodysplastic syndrome.
When does the Decitabine/Tetrahydrouridine (EpiDestiny/Novo Nordisk) patent expire?
No public expiry year is available for Decitabine/Tetrahydrouridine (EpiDestiny/Novo Nordisk) yet; this page updates once verified.
How do I get a quote for Decitabine/Tetrahydrouridine (EpiDestiny/Novo Nordisk) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05